Innate Pharma (IPHA) Establishes New At-The-Market Program on Nasdaq
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Innate Pharma Establishes a New At-The-Market (“ATM”) Program on Nasdaq
April 26, 2023 4:50 PM EDTMARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that it has filed a prospectus supplement with the Securities and Exchange Commission (SEC) relating to a new At-The-Market (ATM) program. Pursuant to this program, the Company may offer and sell to eligible investors (as described below) a total gross amount of up to $75 million of American Depositary Shares (ADS), each ADS representing one ordinary share of Innate, from time to time in sales deemed to be an at the market offering... More
